TD Cowen Upgrades UnitedHealth to Buy
The brokerage raised its price target on the insurer to $455 from $402, citing Optum Health recovery and earnings growth potential.
Updated on Nov. 20, 2026 in Healthcare

Live Poll
Do you trust large health insurance companies to treat patients fairly?
TD Cowen upgraded UnitedHealth to buy from hold and raised its price target to $455 from $402. The new target implies 38% upside from Thursday's close, after the shares declined 14% over the past three months.
Why it matters
The upgrade comes as policy headwinds have mounted for the insurer, including a proposed anti-fraud rule from the Centers for Medicare & Medicaid Services. Analysts see a possible recovery in the company's Optum Health unit as a key driver of future earnings.
TD Cowen's new $455 target sits 38% above Thursday's close, while 25 of the 28 analysts covering UnitedHealth rate the stock buy or strong buy. The source does not indicate how the 14% three-month share decline compares with the broader managed care sector.
The players
UnitedHealth
UnitedHealth is a large American health insurer and healthcare company whose Optum unit operates care delivery and health services businesses.
Centers for Medicare & Medicaid Services
The Centers for Medicare & Medicaid Services is the federal agency that administers Medicare, Medicaid and related health programs.
The details
TD Cowen analyst Ryan Langston wrote that UnitedHealth has a credible path toward mid-high-teens EPS growth through at least 2028. The upgrade rests on Medicare Advantage benefit design, an Optum Health recovery, and improvement in commercial and Medicare-Medicaid Dual Complete businesses.
Timeline
Earlier in November 2026: CMS put forth a proposed anti-fraud rule targeting Medicare and Medicare Advantage programs.
November 20, 2026: TD Cowen upgraded UnitedHealth to buy and raised its price target to $455.
2027: Optum Health is expected to deliver another year of solid margin expansion.
Market Landscape
The upgrade weighs a proposed CMS anti-fraud rule aimed at Medicare Advantage against UnitedHealth's Optum Health recovery. TD Cowen's view places the insurer's earnings path against the regulatory pressure now facing the Medicare Advantage market.
Shares of UnitedHealth remain a focus for investors weighing the upgrade against recent declines. Consumers enrolled in Medicare Advantage plans may see effects if the proposed CMS anti-fraud rule changes how those plans operate.
The takeaway
Analyst ratings reflect a view on future earnings, not a guarantee of share performance. Readers tracking the insurer should watch how the proposed CMS rule and Optum Health results develop.
Further reading
Track more coverage in the Healthcare section.
Live Poll
Do you trust large health insurance companies to treat patients fairly?






